Eli Lilly Shares Rise After Drug Helps Patients Lose More Weight Than Competitors
Eli Lilly shares rose in early trading on Tuesday after a trial showed its retatrutide weight loss drug could help patients lose more weight than other drugs, including Novo Nordisk's Ozempic.
Eli Lilly shares rose in early trading on Tuesday after a trial showed its retatrutide weight loss drug could help patients lose more weight than other drugs, including Novo Nordisk's Ozempic.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1363267262-46185a80ce6d4e51bc995f87c5a2e19e.jpg?#){kind=small}
:max_bytes(150000):strip_icc()/car-dealer-is-giving-key-for-a-new-car-to-a-businesswoman-923418762-5bde746a4cedfd0026446af5.jpg){kind=small}
:max_bytes(150000):strip_icc()/5thAveAppleStore-56a5d5153df78cf7728a0f9d.jpg){kind=small}
:max_bytes(150000):strip_icc()/investopedia-social-share-default-ab113c8afd9a439dbc4c68b1926292f4.png){kind=small}
